Economic burden of community-acquired pneumonia among elderly patients: a Japanese perspective
Tóm tắt
This study aimed to estimate the economic burden of community-acquired pneumonia (CAP) among elderly patients in Japan. In addition, the study evaluated the relationship between total treatment cost and CAP risk factors. An administrative database was searched for elderly patients (≥ 65 years old) who had pneumonia (ICD-10 code: J12–J18) and an antibiotic prescription between 1 June 2014 and 31 May 2015. The all-cause total healthcare costs of outpatient and inpatient CAP episodes were calculated. This study evaluated data from 29,619 patients with CAP who experienced 14,450 outpatient CAP episodes and/or 20,314 inpatient CAP episodes. The mean ages were 77.5 ± 8.0 years and 81.5 ± 8.2 years among the outpatient and inpatient groups, respectively. The median treatment costs were US$346 (interquartile range: $195–551) per outpatient episode and US$4851 (interquartile range: $3313–7669) per inpatient episode. More severe cases had increased treatment costs at the treating hospitals. Male sex, diabetes, chronic obstructive pulmonary disease, and liver dysfunction were associated with increased total treatment costs, while dementia, dialysis, and rheumatism were associated with high costs of treating a CAP episode. The economic burden of CAP might be decreased by reducing the number of hospitalizations for mild CAP and the incidence of severe CAP. Therefore, preventative care (e.g. oral hygiene or pneumococcus vaccination) is recommended for patients with related risk factors, such as male sex, older age, diabetes, chronic obstructive pulmonary disease, liver dysfunction, rheumatism, dementia, or dialysis.
Tài liệu tham khảo
Morimoto K, Suzuki M, Ishifuji T, et al. The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study. PLoS One. 2015;10:1–18.
Farr BM, Woodhead MA, MacFarlane JT, et al. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Respir Med. 2000;94:422–7.
Baik I, Curhan GC, Rimm EB, et al. A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women. Arch Intern Med. 2000;160:3082–8.
Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39:1642–50.
Vila Corcoles A, Ochoa Gondar O, Rodriguez Blanco T, et al. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med. 2009;103:309–16.
Millett ERC, De Stavola BL, Quint JK, et al. Risk factors for hospital admission in the 28 days following a community-acquired pneumonia diagnosis in older adults, and their contribution to increasing hospitalisation rates over time: a cohort study. BMJ Open. 2015;5:e008737.
Benjamin AL, Edward JB, Thomas SI, et al. Risk factors for acquiring pneumococcal infections. Arch Intern Med. 1986;146:2179–85.
Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med. 1994;96:313–20.
Almirall J, Bolíbar I, Balanzó X, et al. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J. 1999;13:349–55.
Sanz Herrero F, Blanquer OJ. Microbiology and risk factors for community-acquired pneumonia. Semin Respir Crit Care Med. 2012;33:220–31.
Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community acquired pneumonia. N Engl J Med. 1997;336:243–50.
Sato R, Gomez Rey G, Nelson S, et al. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged >/=50 years. Appl Health Econ Health Policy. 2013;11:251–8.
File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in north American adults. Postgrad Med. 2010;122:130–41.
Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29:3398–412.
Reyes S, Martinez R, Vallés JM, et al. Determinants of hospital costs in community-acquired pneumonia. Eur Respir J. 2008;31:1061–7.
Cascini S, Agabiti N, Incalzi RA, et al. Pneumonia burden in elderly patients: a classification algorithm using administrative data. BMC Infect Dis. 2013;13:559.
Tichopad A, Roberts C, Gembula I, et al. Clinical and economic burden of community-acquired pneumonia among adults in the Czech Republic, Hungary, Poland and Slovakia. PLoS One. 2013;8:e71375.
Yoo KH, Yoo CG, Kim SK, et al. Economic burden and epidemiology of pneumonia in Korean adults aged over 50 years. J Korean Med Sci. 2013;28:888–95.
Thomas CP, Ryan M, Chapman JD, et al. Incidence and cost of pneumonia in medicare beneficiaries. Chest. 2012;142:973–81.
Kawakami K, Ohkusa Y, Kuroki R, et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine. 2010;28:7063–9.
Rozenbaum MH, Mangen MJ, Huijts SM, et al. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: a nationwide retrospective claims database analysis. Vaccine. 2015;33:3193–9.
Bartolomé M, Almirrall J, Morera J, et al. A population-based study of the costs of care for community-acquired pneumonia. Eur Respir J. 2004;23:610–6.
Bauer TT, Welte T, Ernen C, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest. 2005;128:2238–46.
Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA. 1993;270:1826–31.
Poethko Müller C, Schmitz R. Vaccination coverage in German adults: Results of the German Health Interview and Examination Survey for Adults (DEGS1). Vol. 56. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz; 2013. p. 845–57.
Australian Institute of Health and Welfare. 2009 Adult vaccination survey: summary results. 2011. http://www.aihw.gov.au/publication-detail/?id=10737418409. Accessed 15 Apr 2017.
Yoneyama T, Yoshida M, Ohrui T, et al. Oral care reduces pneumonia in older patients in nursing homes. J Am Geriatr Soc. 2002;50:430–3.
Nakamura K. Diagnosis procedure combination database would develop Nationwide clinical research in Japan. Japanese Circ Soc. 2016;80:2289–90.
Milea D, Azmi S, Reginald P, et al. A review of accessibility of administrative healthcare databases in the Asia-Pacific region. J Mark Access Health Policy. 2015. doi.10.3402/jmahp.v3.28076.
Tanaka S, Seto K, Kawakami K. Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Heal Care Sci. 2015. doi.10.1186/s40780-015-0016-5.
Uematsu H, Kunisawa S, Yamashita K, et al. The impact of patient profiles and procedures on hospitalization costs through length of stay in community-acquired pneumonia patients based on a Japanese administrative database. PLoS One. 2015;10:1–13.
Shindo Y, Sato S, Maruyama E, et al. Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia. Respirology. 2008;13:731–5.
Miyashita N, Matsushima T, Oka M, et al. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med. 2006;45:419–28.
Cupurdija V, Lazic Z, Petrovic M, et al. Community-acquired pneumonia: economics of inpatient medical care vis-à-vis clinical severity. J Bras Pneumol. 2015;41:48–57.
Choudhury G, Chalmers JD, Mandal P, et al. Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients. Eur Respir J. 2011;38:643–8.
Aliberti S, Ramirez J, Cosentini R, et al. Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia. Respir Med. 2011;105:1732–8.
Spoorenberg SM, Bos WJ, Heijligenberg R, et al. Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysis. BMC Infect Dis. 2014;14:335.